SCHEMBL613332

SCHEMBL613332

O=C(O)c1c[nH]c2cc(Cl)ccc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.74
F3 P13726 1/20 0.74
NR4A2 P43354 2/20 0.69
AVPR1A P37288 2/20 0.54
PRKAB2 O43741 5/20 0.54
PRKAG1 P54619 5/20 0.54
PRKAA2 P54646 5/20 0.54
PRKAA1 Q13131 5/20 0.54
PRKAG3 Q9UGI9 5/20 0.54
PRKAG2 Q9UGJ0 5/20 0.54
PRKAB1 Q9Y478 5/20 0.54
GPR84 Q9NQS5 1/20 0.53
ALDH1A1 P00352 2/20 0.50
TP53 P04637 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
CYP2C9 P11712 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30392504 1.00 F7 (0.74) F7F3NR4A2AVPR1APRKAB2
Ammonia Solution, Strong SCHEMBL4556453 0.98 F7 (0.72) F7F3NR4A2AVPR1APRKAB2
SCHEMBL2965244 0.90 F7 (0.66) F7F3NR4A2ALDH1A1KDM4E
SCHEMBL30906941 0.90 F7 (0.66) F7F3NR4A2ALDH1A1KDM4E
SCHEMBL840574 0.88 NR4A2 (0.63) F7F3NR4A2AVPR1AGPR84
SCHEMBL26204498 0.86 NR4A2 (0.65) F7F3NR4A2AVPR1AGPR84
SCHEMBL3182218 0.86 NR4A2 (0.69) F7F3NR4A2AVPR1AGPR84
SCHEMBL1434913 0.85 F7 (1.00) F7F3NR4A2PRKAB2PRKAG1
SCHEMBL17423792 0.84 MAPT (0.64) F7F3NR4A2AVPR1AGPR84
SCHEMBL7538181 0.84 NR4A2 (0.63) F7F3NR4A2AVPR1AGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4660193-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2025-12-10 EP disclosed
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-11-13 US disclosed
EP-4431505-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2024-09-18 EP disclosed
WO-2024162746-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF 한국화학연구원 2024-08-08 WO disclosed
CN-118234721-A Isoindolinone derivative with glutarimide mother nucleus and application thereof 韩国化学研究院 2024-06-21 CN disclosed
WO-2024109642-A1 USE OF BENZOAZACYCLIC COMPOUND AS ALLOSTERIC MODULATOR OF β2-ADRENOCEPTOR 常州大学 2024-05-30 WO disclosed
CN-117756785-A Preparation and application of N- (pyridine-2-yl) benzo [ b ] five-membered heterocycle-3-carboxamide structure compound 江西中医药大学 2024-03-26 CN disclosed
CN-117603120-A Preparation method and application of indole-3-fluoroketone compound 平顶山学院 2024-02-27 CN disclosed
CN-117447381-A Indole amide derivative and its application in preparing beta 2 Use of adrenoreceptor allosteric antagonist medicaments 常州大学 2024-01-26 CN disclosed
US-20230271941-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-31 US disclosed
US-20070072888-A1 Indol-3-yl-carbonyl-azaspiro derivatives F. HOFFMAN-LA ROCHE AG (CH) 2007-03-29 US disclosed
WO-2007014851-A2 INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-02-08 WO disclosed
US-20070027173-A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2007-02-01 US disclosed
US-20070027163-A1 Indol-3-y-carbonyl-piperidin and piperazin-derivatives HOFFMANN-LA ROCHE INC. 2007-02-01 US disclosed
WO-2007009906-A1 INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-25 WO disclosed
US-20070021463-A1 Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives HOFFMANN-LA ROCHE INC. 2007-01-25 US disclosed
WO-2007006688-A1 INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-18 WO disclosed
EP-1603572-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2005-12-14 EP disclosed
US-20040204454-A1 Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed
WO-2004082687-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027173-A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists AVPR1A, AVPR2, AVPR1B F7 3842/4885F3 1290/4885NR4A2 952/4885
US-20040204454-A1 Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors PEPD, TFPI, F2 F7 53/4885F3 43/4885NR4A2 3672/4885
US-20070027163-A1 Indol-3-y-carbonyl-piperidin and piperazin-derivatives AVPR1A, AVPR2, OXTR F7 3461/4885F3 591/4885NR4A2 1606/4885
US-20070021463-A1 Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives AVPR1A, AVPR2, AVPR1B F7 2495/4885F3 672/4885NR4A2 1974/4885
US-20230271941-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 F7 4066/4885F3 4163/4885NR4A2 2070/4885
US-20070072888-A1 Indol-3-yl-carbonyl-azaspiro derivatives AVPR1A, AVPR2, AVPR1B F7 3578/4885F3 1137/4885NR4A2 968/4885
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF CRBN, IDH1, IDH2 F7 4871/4885F3 4454/4885NR4A2 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.